



Realignment in Intercell's Supervisory Board

Vienna (Austria), February 3, 2006 – Intercell AG (VSE, "ICLL") today announced the following realignment in its Supervisory Board:

Luke Evnin, general partner at the private equity firm MPM Capital L.P., who joined Intercell's Supervisory Board in July 2004, resigns from his position in Intercell's Supervisory Board.

The Board of Directors would like to take this opportunity to thank Luke Evnin for his long and good cooperation.

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for prevention and treatment of diseases for which there exists substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and *S. aureus* which are in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2 - A-1030 Vienna

P: +43-1-20620-303 – kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.